Addiction (Abingdon, England) · 2008
Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kheirabadi Gholam R, Ranjkesh Mansour, Maracy Mohamad R, Salehi Mehrdad
Аннотация
AIMS: Evaluation of the efficacy of gabapentin in patients undergoing out-patient treatment for opiate withdrawal.
DESIGN: A 3-week double-blind, randomized, placebo-controlled trial of adjunctive gabapentin in methadone-assisted detoxification (MAD).
SETTING: Specialized Addictive Behaviors Unit, an out-patient unit for the treatment of patients with an addictive disorder serving the city of Isfahan (Iran).
PARTICIPANTS: Forty out-patients, 37 males and three females, aged 21-61 years, who met DSM-IV criteria for opiate dependence.
INTERVENTION: Random assignment of subjects to receive adjunctive treatment with either gabapentin (900 mg/day) or placebo under double-blind conditions.
MEASUREMENTS: Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages.
FINDINGS: Despite the superiority of gabapentin on controlling some of withdrawal symptoms, no significant differences were reported between two groups.
CONCLUSIONS: Dosage of 900 mg/day of gabapentin is not significantly superior to placebo in controlling opiate withdrawal symptoms.
DESIGN: A 3-week double-blind, randomized, placebo-controlled trial of adjunctive gabapentin in methadone-assisted detoxification (MAD).
SETTING: Specialized Addictive Behaviors Unit, an out-patient unit for the treatment of patients with an addictive disorder serving the city of Isfahan (Iran).
PARTICIPANTS: Forty out-patients, 37 males and three females, aged 21-61 years, who met DSM-IV criteria for opiate dependence.
INTERVENTION: Random assignment of subjects to receive adjunctive treatment with either gabapentin (900 mg/day) or placebo under double-blind conditions.
MEASUREMENTS: Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages.
FINDINGS: Despite the superiority of gabapentin on controlling some of withdrawal symptoms, no significant differences were reported between two groups.
CONCLUSIONS: Dosage of 900 mg/day of gabapentin is not significantly superior to placebo in controlling opiate withdrawal symptoms.